Building momentum for subsets of patients with advanced triple-negative breast cancer

Affiliations

Comment

Wendy A Woodward. Lancet Oncol. 2020 Jan.

. 2020 Jan;21(1):3-5.

doi: 10.1016/S1470-2045(19)30737-5. Epub 2019 Nov 27.

¹ Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: wwoodward@mdanderson.org.

No abstract available

Comment on

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators. Schmid P, et al. Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27. Lancet Oncol. 2020. PMID: 31786121 Clinical Trial.